Related Experiment Video
Updated: Jul 6, 2026
11:18
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Translating trial data into patients benefits: making the right choice
1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, Building J-3, Torrance, CA 90502, USA. rchlebowski@gmail.com
Breast (Edinburgh, Scotland)
|March 28, 2008
Summary
Aromatase inhibitors (AIs) offer superior efficacy and safety over tamoxifen for early breast cancer adjuvant therapy in postmenopausal women. Early AI initiation maximizes patient benefits by reducing recurrence and adverse events.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Tamoxifen has been a long-standing adjuvant therapy for early breast cancer in postmenopausal women.
- Tamoxifen use is linked to significant adverse events, prompting a search for alternatives.
- Aromatase inhibitors (AIs) are emerging as a preferred treatment due to better tolerability and efficacy.
Purpose of the Study:
- To review and compare the efficacy, safety, and patient benefits of AIs versus tamoxifen in adjuvant hormonal therapy for postmenopausal breast cancer.
- To evaluate the current understanding of AI and tamoxifen use in clinical practice.
- To determine the optimal timing for initiating AI therapy.
Main Methods:
- Systematic literature review of clinical trials and observational studies.
- Comparative analysis of efficacy data (e.g., recurrence rates).
- Assessment of safety profiles and adverse event reporting for both drug classes.
Main Results:
- Aromatase inhibitors demonstrate a significant advantage over tamoxifen in efficacy.
- The greatest differences in outcomes between AIs and tamoxifen are observed within the first 1-2 years of treatment.
- AIs are generally better tolerated, leading to fewer treatment-related adverse events.
Conclusions:
- Aromatase inhibitors represent a superior treatment option compared to tamoxifen for adjuvant therapy in postmenopausal early breast cancer.
- Early initiation of AI therapy is recommended to maximize patient benefits and minimize risks.
- Switching to or starting with an AI at the earliest opportunity is crucial for preventing cancer recurrence and managing adverse events effectively.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...